Bristol-Myers Squibb Co
BRM
Company Profile
Business description
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
32,500
Stocks News & Analysis
stocks
Nvidia: Hugging Face acquisition both a wise offensive and defensive move
We think this improves Nvidia’s position within the open-source community.
stocks
Anthropic’s IPO will be huge—and risky. Here are the challenges investors should watch
Part two of a Q&A with PitchBook senior analyst Harrison Rolfes about Anthropic, the AI giant’s challenges, and how much it’s worth.
stocks
Chart of the Week: China demand for copper falls amidst record rally
Elevated copper prices raise valuation questions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,188.40 | 62.20 | -0.67% |
| CAC 40 | 8,286.40 | 5.77 | 0.07% |
| DAX 40 | 26,003.32 | 163.99 | 0.63% |
| Dow JONES (US) | 53,686.11 | 624.16 | 1.18% |
| FTSE 100 | 10,831.52 | 75.07 | 0.70% |
| HKSE | 25,737.60 | 524.29 | 2.08% |
| NASDAQ | 26,584.06 | 366.23 | 1.40% |
| Nikkei 225 | 64,963.16 | 748.68 | 1.17% |
| NZX 50 Index | 13,934.40 | 88.22 | 0.64% |
| S&P 500 | 7,747.71 | 81.11 | 1.06% |
| S&P/ASX 200 | 8,999.80 | 70.40 | -0.78% |
| SSE Composite Index | 3,955.85 | 13.76 | 0.35% |